Story perspectives

Takeda Partners with Iambic for $1.7B AI Drug Discovery

2/10/2026

Summary

Story summary

Takeda Pharmaceuticals has entered a multiyear partnership with Iambic Therapeutics valued at over $1.7 billion to boost AI-enabled drug discovery.
The collaboration aims to develop small molecule drugs for cancer and GI conditions.
Tom Miller, Iambic Therapeutics' chief executive officer, emphasizes the partnership aims to validate their technology.
The deal follows Iambic's recent successes, including a $100 million fundraise and collaborations with other firms.

1 of 1

Story summary

Takeda Pharmaceuticals has entered a multiyear partnership with Iambic Therapeutics valued at over $1.7 billion to boost AI-enabled drug discovery.
The collaboration aims to develop small molecule drugs for cancer and GI conditions.
Tom Miller, Iambic Therapeutics' chief executive officer, emphasizes the partnership aims to validate their technology.
The deal follows Iambic's recent successes, including a $100 million fundraise and collaborations with other firms.